Newsletter - View InhalteNewsletter2023

ID	424
Newsletter2023	2023-11-16
Element	9926
Info	[Universal 2023] [Teaser] Teaser Indikationserweiterung für Skyrizi (SO) (9926)
Position	3
html	<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="right" style="padding:0;Margin:0;padding-bottom:5px;padding-top:6px;padding-right:0;padding-left:20px;background-color: #e0e0e0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p> </td> </tr> <tr> <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px"> <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Indikationserweiterung für Skyrizi<sup style="line-height:0">®</sup></h2> </td> </tr> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px"> <!--[if mso]> <table style="width:660px" cellpadding="0" cellspacing="0"> <tr> <td style="width:340px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:340px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Der IL-23-Inhibitor (Wirkstoff Risankizumab) ist nun auch zur Behandlung des mittelschweren bis schweren Morbus Crohn zugelassen. Die Therapieinduktion erfolgt via Infusion mit Skyrizi<sup style="line-height:0">®</sup> 600 mg in Woche 0, 4 und 8. Ab Woche 12 beginnt die Erhaltungstherapie, die sich Patientinnen und Patienten alle 8 Wochen selbst mit Hilfe des On-Body-Injektors (OBI) applizieren.</p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> <td style="width:20px"></td> <td style="width:320px" valign="top"> <![endif]--> <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;width:320px"> <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0"> <img alt="" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2023q3/newsletter_2023-09-27_g1.jpg"> </td> </tr> <tr> <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">© AbbVie Deutschland GmbH & Co. KG</p> <br> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> <!--[if mso]> </td> </tr> </table> <![endif]--> </td> </tr> <tr> <td align="center" style="Margin:0; padding: 20px 20px 10px 20px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0"> <tbody> <tr> <td align="center" style="border-radius: 0px;" bgcolor="#005CA9"> <a href="https://www.abbviepro.com/c/snePib?utm_medium=advertorial&utm_source=AbbVie-abbPro-de&utm_campaign=DE_SKY_IMM_CD_DAP_Newsletter_OBI&utm_id=DE-2023-IMM-SKY-CD-66" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Mehr zur Anwendung</a> </td> </tr> </tbody> </table> </td> </tr> <tr> <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0"> <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td> </tr> </tbody> </table> </td> </tr> <tr> <td align="left" style="Margin:0; padding: 10px 20px 10px;"> <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="310"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;"> <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">» <a href="https://www.arzneimittelsuche.abbvie.de/content/dam/abbvie-sitegenerator-ous/arzneimittelsuche/pflichttexte/SKYRIZI-600mg-360mg.pdf" target="_blank" style="mso-line-height-rule:exactly;text-decoration:none;font-size:12px;color:#005CA9">Pflichttext (PDF)</a></p> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>

Newsletter2023

2023-11-16

Info

[Universal 2023] [Teaser] Teaser Indikationserweiterung für Skyrizi (SO) (9926)

html

<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important">
    <tbody>
        <tr>
            <td align="center" style="padding:0;Margin:0">
                <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px;border-width:0" cellspacing="0" cellpadding="0" align="center">
                    <tbody>
                        <tr>
                            <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px">
                                <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px">
                                    <tbody>
                                        <tr>
                                            <td valign="top" align="center" style="padding:0;Margin:0;width:660px">
                                                <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-width:0;border-radius:0;background-color:#ffffff" bgcolor="#ffffff">
                                                    <tbody>
                                                        <tr>
                                                            <td align="right" style="padding:0;Margin:0;padding-bottom:5px;padding-top:6px;padding-right:0;padding-left:20px;background-color: #e0e0e0;">
                                                                <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#777777;font-size:12px !important;"><span style="background:transparent">Anzeige</span></p>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="left" style="Margin:0;padding-right:20px;padding-left:20px;padding-top:20px;padding-bottom:0px">
                                                                <h2 style="Margin:0;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;mso-line-height-rule:exactly;letter-spacing:0;font-size:20px;font-style:normal;font-weight:bold;line-height:24px;color:#005CA9">Indikationserweiterung für Skyrizi<sup style="line-height:0">®</sup></h2>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="left" bgcolor="transparent" style="padding:0;Margin:0;background-color:#ffffff;padding-top:20px">
                                                                <!--[if mso]>
                                                                <table style="width:660px" cellpadding="0" cellspacing="0">
                                                                    <tr>
                                                                        <td style="width:340px" valign="top">
                                                                            <![endif]-->
                                                                            <table cellpadding="0" cellspacing="0" class="es-left" align="left" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:left">
                                                                                <tbody>
                                                                                    <tr>
                                                                                        <td align="left" style="padding:0;Margin:0;width:340px">
                                                                                            <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff">
                                                                                                <tbody>
                                                                                                    <tr>
                                                                                                        <td align="left" bgcolor="transparent" style="padding:0;Margin:0;padding-right:0;padding-left:20px;padding-right:20px;padding-top:0px;">
                                                                                                            <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">Der IL-23-Inhibitor (Wirkstoff Risankizumab) ist nun auch zur Behandlung des mittelschweren bis schweren Morbus Crohn zugelassen. Die&nbsp;Therapieinduktion erfolgt via Infusion mit Skyrizi<sup style="line-height:0">®</sup> 600&nbsp;mg in Woche 0, 4 und 8. Ab&nbsp;Woche 12 beginnt die Erhaltungstherapie, die sich Patientinnen und Patienten alle 8&nbsp;Wochen selbst mit Hilfe des On-Body-Injektors (OBI) applizieren.</p>
                                                                                                        </td>
                                                                                                    </tr>
                                                                                                </tbody>
                                                                                            </table>
                                                                                        </td>
                                                                                    </tr>
                                                                                </tbody>
                                                                            </table>
                                                                            <!--[if mso]>
                                                                        </td>
                                                                        <td style="width:20px"></td>
                                                                        <td style="width:320px" valign="top">
                                                                            <![endif]-->
                                                                            <table cellpadding="0" cellspacing="0" class="es-right" align="right" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;float:right">
                                                                                <tbody>
                                                                                    <tr>
                                                                                        <td align="left" style="padding:0;Margin:0;width:320px">
                                                                                            <table cellpadding="0" cellspacing="0" width="100%" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:#ffffff" bgcolor="#ffffff">
                                                                                                <tbody>
                                                                                                    <tr>
                                                                                                        <td align="center" style="padding:0;Margin:0;padding-right:20px;font-size:0" class="pt-20 pr-0">
                                                                                                            <img alt="" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none" src="https://www.deutschesapothekenportal.de/newsletter/2023q3/newsletter_2023-09-27_g1.jpg">
                                                                                                        </td>
                                                                                                    </tr>
                                                                                                    <tr>
                                                                                                        <td align="right" class="es-text-3633" style="padding:0;Margin:0;padding-right:20px;font-size:12px">
                                                                                                            <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:18px;letter-spacing:0;color:#555;font-size:12px">© AbbVie Deutschland GmbH &amp; Co. KG</p>
                                                                                                            <br>
                                                                                                        </td>
                                                                                                    </tr>
                                                                                                </tbody>
                                                                                            </table>
                                                                                        </td>
                                                                                    </tr>
                                                                                </tbody>
                                                                            </table>
                                                                            <!--[if mso]>
                                                                        </td>
                                                                    </tr>
                                                                </table>
                                                                <![endif]-->
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="center" style="Margin:0; padding: 20px 20px 10px 20px;">
                                                                <table role="presentation" border="0" cellspacing="0" cellpadding="0">
                                                                    <tbody>
                                                                        <tr>
                                                                            <td align="center" style="border-radius: 0px;" bgcolor="#005CA9">
                                                                                <a href="https://www.abbviepro.com/c/snePib?utm_medium=advertorial&amp;utm_source=AbbVie-abbPro-de&amp;utm_campaign=DE_SKY_IMM_CD_DAP_Newsletter_OBI&amp;utm_id=DE-2023-IMM-SKY-CD-66" target="_blank" style="font-size: 14px; font-family: Open Sans, Helvetica, Arial, sans-serif; color: #ffffff; text-decoration: none;background-color: #005CA9; padding: 10px 20px; border: 1px solid #005CA9; display: block;">Mehr zur Anwendung</a>
                                                                            </td>
                                                                        </tr>
                                                                    </tbody>
                                                                </table>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="center" style="padding:0;Margin:0;padding-left:20px;padding-right:20px; font-size:0">
                                                                <table border="0" width="100%" height="100%" cellpadding="0" cellspacing="0" class="es-spacer" role="presentation" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px">
                                                                    <tbody>
                                                                        <tr>
                                                                            <td style="padding:0;Margin:0;border-bottom:1px solid #b0b0b0;background:none;height:1px;width:100%;margin:0"></td>
                                                                        </tr>
                                                                    </tbody>
                                                                </table>
                                                            </td>
                                                        </tr>
                                                        <tr>
                                                            <td align="left" style="Margin:0; padding: 10px 20px 10px;">
                                                                <table role="presentation" border="0" cellspacing="0" cellpadding="0" width="310">
                                                                    <tbody>
                                                                        <tr>
                                                                            <td align="left" style="padding:0;Margin:0;">
                                                                                <p style="Margin:0;mso-line-height-rule:exactly;font-family:helvetica, 'helvetica neue', arial, verdana, sans-serif;line-height:20px;letter-spacing:0;color:#555555;font-size:14px">» <a href="https://www.arzneimittelsuche.abbvie.de/content/dam/abbvie-sitegenerator-ous/arzneimittelsuche/pflichttexte/SKYRIZI-600mg-360mg.pdf" target="_blank" style="mso-line-height-rule:exactly;text-decoration:none;font-size:12px;color:#005CA9">Pflichttext (PDF)</a></p>
                                                                            </td>
                                                                        </tr>
                                                                    </tbody>
                                                                </table>
                                                            </td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </td>
        </tr>
    </tbody>
</table>

View InhalteNewsletter2023 #424